WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Monday, April 24, 2006

Hide?	Set Name	Query	Hit Count
	DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=OR		
☐	L3	L2 same (interferon or IFN)	29
☐	L2	L1 same blood	504
☐	L1	(oligoadenylate adj sythetase) or OAS	817326

END OF SEARCH HISTORY

AB CpG oligocleoxynucleotides (CpG-ODNs) affect innate and adaptive immune
responses, including antigen presentation, costimulatory molecule
expression, dendritic cell maturation, and induction of cytokines
enhancing antibody-dependent cell-mediated cytotoxicity (ADCC). We
conducted a phase 1 study evaluating 4 dose levels of a CpG-ODN (11018
ISS) with rituximab in 20 patients with relapsed non-Hodgkin lymphoma
(NHL). Patients received CpG once a week for 4 weeks beginning after the
second of 4 rituximab infusions. Adverse events were minimal.
Quantitative polymerase chain reaction (PCR) measurements of a panel of
genes inducible by CpG-ODN and interferons were performed on blood samples
collected before and 24 hours after CpG. A dose-related increase was
measured in the expression of several interferon-inducible genes after CpG
and correlated with serum levels of 2'-5' oligoadenylate synthetase (OAS),
a validated interferon response marker. Genes induced selectively by
interferon-gamma (IFN-gamma) were not significantly induced by CpG. In
conclusion, we have defined a set of gene expression markers that provide
a sensitive measure of biologic responses of patients to CpG therapy in a
dose-related manner. Moreover. all the genes significantly induced by
this CpG are regulated by type 1 interferons. providing insight into the
dominant immune mechanisms in humans. CpG treatment resulted in no
significant toxicity, providing ration-ale for further testing of this
exciting combination immunotherapy approach to NHL. Copyright 2005 by The
American Society of Hematology.

L4 ANSWER 5 OF 9 USPATFULL on STN
ACCESSION NUMBER: 2004:177784 USPATFULL
TITLE: Branched immunomodulatory compounds and methods of
using the same
INVENTOR(S): Fearon, Karen L., Lafayette, CA, UNITED STATES
PATENT ASSIGNEE(S): Dynavax Technologies Corporation (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004136948	A1	20040715
APPLICATION INFO.:	US 2003-739518	A1	20031217 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-436406P	20021223 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MORRISON & FOERSTER LLP, 755 PAGE MILL RD, PALO ALTO,
CA, 94304-1018
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Page(s)
LINE COUNT: 4780
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides immunomodulatory compounds and methods for
immunomodulation of cells and individuals using the immunomodulatory
compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 6 OF 9 USPATFULL on STN
ACCESSION NUMBER: 2004:172513 USPATFULL
TITLE: Chimeric immunomodulatory compounds and methods of
using the same-IV
INVENTOR(S): Fearon, Karen L., Lafayette, CA, UNITED STATES
Dina, Dino, Oakland, CA, UNITED STATES
Tuck, Stephen F., Oakland, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004132677	A1	20040708
APPLICATION INFO.:	US 2003-623371	A1	20030718 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2002-328578, filed

on 23 Dec 2002, PENDING Continuation-in-part of Ser.
No. US 2002-176883, filed on 21 Jun 2002, PENDING
Continuation-in-part of Ser. No. US 2002-177826, filed
on 21 Jun 2002, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-299883P	20010621 (60)
	US 2002-375253P	20020423 (60)
	US 2002-375253P	20020423 (60)
	US 2001-299883P	20010621 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MORRISON & FOERSTER LLP, 755 PAGE MILL RD, PALO ALTO,
CA, 94304-1018
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 21 Drawing Page(s)
LINE COUNT: 8072
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides immunomodulatory compounds and methods for immunomodulation of individuals using the immunomodulatory compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 7 OF 9 USPATFULL on STN
ACCESSION NUMBER: 2004:7759 USPATFULL
TITLE: Method for preparation of large volume batches of
poly-ICLC with increased biological potency;
therapeutic, clinical and veterinary uses thereof
INVENTOR(S): Salazar, Andres, Washington, DC, UNITED STATES
PATENT ASSIGNEE(S): ONCOVIR, INC. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005998	A1	20040108
APPLICATION INFO.:	US 2003-611614	A1	20030701 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-393713P	20020703 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Max Stul Oppenheimer, P.O. Box 50, Stevenson, MD, 21153
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Page(s)
LINE COUNT: 846
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Method for producing large lots of final sterile Poly-ICLC suitable for
clinical use with reduced toxicity at effective dose levels, and method
for using Poly-ICLC to regulate genes, and method for using Poly-ICLC to
treat certain human and veterinary infectious, neoplastic and autoimmune
disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 8 OF 9 USPATFULL on STN
ACCESSION NUMBER: 2003:319267 USPATFULL
TITLE: Chimeric immunomodulatory compounds and methods of
using the same - III
INVENTOR(S): Fearon, Karen L., Lafayette, CA, UNITED STATES
Dina, Dino, Oakland, CA, UNITED STATES
Tuck, Stephen F., Oakland, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003225016	A1	20031204
APPLICATION INFO.:	US 2002-328578	A1	20021223 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2002-176883, filed

on 21 Jun 2002, PENDING
Continuation-in-part of Ser.
No. US 2002-177826, filed on 21 Jun 2002, PENDING

NUMBER DATE
---------- --------
PRIORITY INFORMATION: US 2001-299883P 20010621 (60)
US 2002-375253P 20020423 (60)
US 2001-299883P 20010621 (60)
US 2002-375253P 20020423 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Randolph T. Apple, Morrison & Foerster LLP, 755 Page
Mill Road, Palo Alto, CA, 94304-1018
NUMBER OF CLAIMS: 33
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 19 Drawing Page(s)
LINE COUNT: 7262
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides immunomodulatory compounds and methods for
immunomodulation of individuals using the immunomodulatory compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 9 OF 9 MEDLINE on STN
ACCESSION NUMBER: 90232662 MEDLINE
DOCUMENT NUMBER: PubMed ID: 1691881
TITLE: [Interferon, oligoadenylate synthetase and oligoadenine
nucleotide--a cell biological triad].
Interferon, oligoadenylatsyntetase og oligoadeninnukleotid--
en cellebiologisk triade.
AUTHOR: Bonnevie-Nielsen V
CORPORATE SOURCE: Odense Sygehus, Klinisk Kemisk Afdeling.
SOURCE: Ugeskrift for laeger, (1990 Apr 16) Vol. 152, No. 16, pp.
1140-3. Ref: 30
Journal code: 0141730. ISSN: 0041-5782.
PUB. COUNTRY: Denmark
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LANGUAGE: Danish
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199005
ENTRY DATE: Entered STN: 6 Jul 1990
Last Updated on STN: 29 Jan 1996
Entered Medline: 31 May 1990
AB In sensitive cells interferon (IFN) induces many genes leading to an
increased production of several different proteins. One of these gene
products is the enzyme oligoadenylatesynthetase (OAS). The main effect of
this IFN induced enzyme activation is the production of oligonucleotides
(2-5A) from cellular ATP. The 2-5A activates an endogeneous ribonuclease
(RNase), which cleaves rRNA and mRNA. The sum of these effects is
degradation of cellular and viral RNA, resulting in reduced protein
synthesis. Taken together, IFN, OAS and 2-5A exist as
a part of immune defence system primarily directed against virus
infections. Furthermore, it is possible that this system under normal,
physiological conditions regulates the growth of somatic cells. The virus
inhibiting effect of IFN has been useful in the treatment of viral
infections and certain types of cancer. Probably, the IFN dependent
enzyme systems will achieve a greater therapeutic significance in the
future.

=> log y
COST IN U.S. DOLLARS
SINCE FILE TOTAL
ENTRY
SESSION
FULL ESTIMATED COST
38.98 43.77

STN INTERNATIONAL LOGOFF AT 12:01:11 ON 24 APR 2006

FULL ESTIMATED COST
4.58 4.79

FILE 'MEDLINE' ENTERED AT 11:54:44 ON 24 APR 2006

FILE 'CAPLUS' ENTERED AT 11:54:44 ON 24 APR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 11:54:44 ON 24 APR 2006
Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 11:54:44 ON 24 APR 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'USPATFULL' ENTERED AT 11:54:44 ON 24 APR 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS
SINCE FILE TOTAL
ENTRY
SESSION
FULL ESTIMATED COST
4.58 9.37

=> s OAs or oligoadenylate (W) sythetase
L1 3600 OAS OR OLIGOADENYLATE (W) SYTHETASE

=> s IFN or interferon
L2 491466 IFN OR INTERFERON

=> s l1 (A) l2
L3 12 L1 (A) L2

=> duplicate remove l3
DUPLICATE PREFERENCE IS 'MEDLINE, CAPLUS, EMBASE, BIOSIS, USPATFULL'
KEEP DUPLICATES FROM MORE THAN ONE FILE? Y/(N):n
PROCESSING COMPLETED FOR L3
L4 9 DUPLICATE REMOVE L3 (3 DUPLICATES REMOVED)

=> d l1- ibib, abs
'L6-' IS NOT A VALID FORMAT
In a multifile environment, a format can only be used if it is valid
in at least one of the files. Refer to file specific help messages
or the STNGUIDE file for information on formats available in
individual files.
REENTER DISPLAY FORMAT FOR ALL FILES (FILEDEFAULT):d l4 1- abs ibib
'D' IS NOT A VALID FORMAT
In a multifile environment, a format can only be used if it is valid
in at least one of the files. Refer to file specific help messages
or the STNGUIDE file for information on formats available in
individual files.
REENTER DISPLAY FORMAT FOR ALL FILES (FILEDEFAULT):l4 1- ibib,abs
'L19' IS NOT A VALID FORMAT
'1-' IS NOT A VALID FORMAT
In a multifile environment, a format can only be used if it is valid
in at least one of the files. Refer to file specific help messages
or the STNGUIDE file for information on formats available in
individual files.
REENTER DISPLAY FORMAT FOR ALL FILES (FILEDEFAULT):ibib,abs

L4 ANSWER 1 OF 9 USPATFULL on STN
ACCESSION NUMBER: 2006:68033 USPATFULL
TITLE: Immunostimulatory sequence oligonucleotides and methods
of using the same
INVENTOR(S): Dina, Dino, Oakland, CA, UNITED STATES
Fearon, Karen L., Lafayette, CA, UNITED STATES
Marshall, Jason, Oakland, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006058254	A1	20060316
APPLICATION INFO.:	US 2003-741720	A1	20031218 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-436122P	20021223 (60)

PATENT INFORMATION: US 2006058254 A1 20060316
APPLICATION INFO.: US 2003-741720 A1 20031218 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-436122P	20021223 (60)
	US 2003-447885P	20030213 (60)
	US 2003-467546P	20030501 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MORRISON & FOERSTER LLP, 755 PAGE MILL RD, PALO ALTO,
CA, 94304-1018, US
NUMBER OF CLAIMS: 35
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 5755
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides immunomodulatory polynucleotides and methods for
immunomodulation of individuals using the immunomodulatory
polynucleotides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 2 OF 9 USPATFULL on STN
ACCESSION NUMBER: 2005:286873 USPATFULL
TITLE: Molecular targets of cancer and aging
INVENTOR(S): Tainsky, Michael A., West Bloomfield, MI, UNITED STATES
Draghici, Sorin, Troy, MI, UNITED STATES
Studitskaia, Olga I., Edison, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005250137	A1	20051110
APPLICATION INFO.:	US 2005-85440	A1	20050321 (11)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. WO 2003-US29624, filed on 22 Sep 2003, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-412228P	20020920 (60)
	US 2003-478548P	20030613 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Amy E. Rinaldo, KOHN & ASSOCIATES, PLLC, Suite 410,
30500 Northwestern Highway, Farmington Hills, MI,
48334, US
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 14 Drawing Page(s)
LINE COUNT: 5555
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A diagnostic tool for use in diagnosing diseases, the tool is a detector
for detecting a presence of an array of markers being used to determine
gene expression changes that are related to cellular immortalization,
the presence of the markers being indicative of a specific disease and
the markers and treatments found by the tool. A tool for interpreting
results of a microarray, wherein the tool is a computer program for
analyzing the results of microrarrays. A method of creating an array of
markers for diagnosing the presence of disease by microarraying sera
obtained from a patient to obtain molecular markers of disease and
detecting markers that are present only in the sera of patients with a
specific disease thereby detecting molecular markers being used to
determine gene expression changes that are related to cellular
immortalization and for use in diagnosing disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 3 OF 9 MEDLINE on STN
DUPLICATE 1

ACCESSION NUMBER: 2005259425 MEDLINE
DOCUMENT NUMBER: PubMed ID: 15899864
TITLE: Mice deficient in oocyte-specific oligoadenylate synthetase-like protein OAS1D display reduced fertility.
AUTHOR: Yan Wei; Ma Lang; Stein Paula; Pangas Stephanie A; Burns Kathleen H; Bai Yuchen; Schultz Richard M; Matzuk Martin M
CORPORATE SOURCE: Department of Pathology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA.
CONTRACT NUMBER: F32 HD046335-01A1 (NICHD)
GM07330 (NIGMS)
HD007165 (NICHD)
HD22681 (NICHD)
HD42500 (NICHD)
SOURCE: Molecular and cellular biology, (2005 Jun) Vol. 25, No. 11, pp. 4615-24.
Journal code: 8109087. ISSN: 0270-7306.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200507
ENTRY DATE: Entered STN: 19 May 2005
Last Updated on STN: 22 Jul 2005
Entered Medline: 21 Jul 2005

AB The double-stranded RNA (dsRNA)-induced interferon response is a defense mechanism against viral infection. Upon interferon activation by dsRNA, 2',5'-oligoadenylate synthetase 1 (OAS1A) is induced; it binds dsRNA and converts ATP into 2',5'-linked oligomers of adenosine (called 2-5A), which activate RNase L that in turn degrades viral and cellular RNAs. In a screen to identify oocyte-specific genes, we identified a novel murine cDNA encoding an ovary-specific 2',5'-oligoadenylate synthetase-like protein, OAS1D, which displays 59% identity with OAS1A. OAS1D is predominantly cytoplasmic and is exclusively expressed in growing oocytes and early embryos. Like OAS1A, OAS1D binds the dsRNA mimetic poly(I-C), but unlike OAS1A, it lacks 2'-5' adenosine linking activity. OAS1D interacts with OAS1A and inhibits the enzymatic activity of OAS1A. Mutant mice lacking OAS1D (Oas1d(-/-)) display reduced fertility due to defects in ovarian follicle development, decreased efficiency of ovulation, and eggs that are fertilized arrest at the one-cell stage. These effects are exacerbated after activation of the interferon/OAS1A/RNase L pathway by poly(I-C). We propose that OAS1D suppresses the interferon/OAS/RNase L-mediated cellular destruction by interacting with OAS1A during oogenesis and early embryonic development.

L4 ANSWER 4 OF 9 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
ACCESSION NUMBER: 2005:104488 BIOSIS
DOCUMENT NUMBER: PREV200500103216
TITLE: Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity.
AUTHOR(S): Friedberg, Jonathan W. [Reprint Author]; Kim, Helen; McCauley, Mary; Hessel, Edith M.; Sims, Paul; Fisher, David C.; Nadler, Lee M.; Coffman, Robert L.; Freedman, Arnold S.
CORPORATE SOURCE: Lymphoma ProgramJames P Wilmot Canc Ctr, Univ Rochester, 601 Elmwood Ave,Box 704, Rochester, NY, 14642, USA

jonathan_friedberg@urmc.rochester.edu
SOURCE: Blood, (January 15 2005) Vol. 105, No. 2, pp. 489-495.
print.
CODEN: BLOOAW. ISSN: 0006-4971.
DOCUMENT TYPE: Article
LANGUAGE: English
ENTRY DATE: Entered STN: 16 Mar 2005
Last Updated on STN: 16 Mar 2005